Search the Newsreel

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Rhythm Pharmaceuticals, Inc. (RYTM) is predicted to surpass Q2 earnings estimates, despite an expected year-over-year decline in earnings but higher revenues. The company's Zacks Earnings ESP of +1.46% combined with a Zacks Rank #3 suggests a strong probability of an earnings beat. Investors will …

Rhythm Pharmaceuticals (RYTM) Projected to Announce Earnings on Tuesday

Rhythm Pharmaceuticals Inc (RYTM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rhythm Pharmaceuticals Inc (RYTM), highlighting its current valuation score of 9.55, which ranks 16th in the Pharmaceuticals industry. The P/E ratio is noted as -33.84, with other key metrics like P/B, P/S, and P/CF not yet disclosed …

IRTC|iRhythm Technologies Inc|Price:112.260|Chg%:+3.060

This article provides a comprehensive stock analysis of iRhythm Technologies Inc (IRTC), highlighting its strong fundamentals, high growth potential, and fair valuation. The company's stock is rated a "Strong Buy" by multiple analysts with a target price of $178.00, indicating a significant upside. Key …

Algorhythm Holdings Inc (RIME) Financial Health: Profitability & Balance Sheet Analysis

Algorhythm Holdings Inc (RIME) holds a financial score of 5.73, ranking 31st out of 34 in its industry, indicating stable financial health but low operating efficiency. The company recently reported a 20.42% year-over-year increase in quarterly revenue to $2.40M and a 44.45% increase in …

Rhythm Pharmaceuticals Inc (RYTM) Cash Flow

This article provides a detailed historical cash flow statement for Rhythm Pharmaceuticals Inc (RYTM), displaying data quarterly and annually across several fiscal years. It includes operational, investing, and financing cash flow metrics, along with explanations of these financial terms and their significance. The data …

Algorhythm Holdings Inc (RIME) Income Statement

This article provides the quarterly and annual income statement data for Algorhythm Holdings Inc (RIME), offering insights into the company's financial performance and operational efficiency. It details various financial metrics including total revenue, cost of revenue, operating expenses, operating profit, income before tax, and …

Form DEF 14A Algorhythm Holdings Inc For: 27 July By Investing.com

This article announces the filing of Form DEF 14A by Algorhythm Holdings Inc. for July 27. It provides a brief mention of the filing without further details on its content or implications. The article appears within a financial news platform that also lists various …

Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for alleged corporate wrongdoing. The firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates …

JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight

JPMorgan initiated coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with an Overweight rating and a $145.00 price target, citing the company's potential to expand its Imcivree drug franchise. The firm believes Imcivree's recent expansion into acquired hypothalamic obesity and future indications like congenital hypothalamic obesity and …

Rhythm Pharmaceuticals Inc (RYTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a brief overview of Rhythm Pharmaceuticals Inc (RYTM), highlighting its current stock price, market capitalization, and regional revenue breakdown. The company's revenue distribution shows significant contributions from both the United States and International markets. Financial data for specific business segments and …

Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?

Rhythm Pharmaceuticals (RYTM) has captured investor interest due to a narrative suggesting it is 26.8% undervalued, with a fair value of $139.47 per share, significantly higher than its current $102.10. This valuation is heavily based on anticipated revenue growth from its drug setmelanotide and …

Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Orbimed Advisors LLC

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by SummitTX Capital L.P.

Algorhythm Settles Liabilities Through Equity Issuance Agreement

Algorhythm Holdings (RIME) has settled approximately $1.93 million in liabilities by issuing up to 5 million shares of common stock to Continuation Capital, Inc. The settlement, approved by a Florida court, aims to reduce debt but may dilute equity holders. Additionally, the company amended …

RIME|Algorhythm Holdings Inc|Price:0.446|Chg%:-0.018

TradingKey provides a comprehensive stock analysis for Algorhythm Holdings Inc (RIME), noting its healthy fundamentals, significant growth potential, and high institutional ownership. The company, an AI technology and consumer electronics holding company, is considered fairly valued and has received a "Buy" rating from analysts …

Rhythm Pharmaceuticals (RYTM) Q1 2023 Earnings Report - Results, Call & Slides

Rhythm Pharmaceuticals (RYTM) released its Q1 2023 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$16.11 against a consensus of -$12.57, and actual revenue of $200.81M compared to an expected $212.19M, although showing significant year-over-year revenue growth …

iRhythm Technologies Inc (IRTC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for iRhythm Technologies Inc (IRTC). It notes that no dividends have been distributed by IRTC over the past five years. The page displays the current stock price, market cap, and links to various …

Algorhythm Holdings Inc (RIME) Earnings Date & Reports & Earnings News

Rhythm Pharmaceuticals, Inc. Revenue Breakdown – FWB:1RV

Rhythm Pharmaceuticals, Inc. (FWB:1RV) generated €165.83 million in revenue last year, with its Therapeutics segment being the top performer, contributing €161.56 million. The United States was the largest geographical contributor, accounting for €113.71 million of the revenue. This data highlights the company's key revenue …

Algorhythm Holdings Inc (RIME) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Algorhythm Holdings Inc (RIME), providing a breakdown of major shareholders and institutional holdings. It lists key shareholders like Streeterville Capital LLC and Jane Street Capital, L.L.C., along with their respective proportions. The report also includes quarterly data …

Algorhythm Holdings (NASDAQ: RIME) may issue 5,000,000 shares to settle claim

Algorhythm Holdings, Inc. (NASDAQ: RIME) has reached a settlement agreement with Continuation Capital, Inc. to resolve a $1,928,014 claim. Under the agreement, Algorhythm may issue up to 5,000,000 shares of common stock in tranches until Continuation Capital receives 120% of the claim amount, with …

Algorhythm amends employment agreements with CEO Gary Atkinson and CFO Alex Andre

Algorhythm entered into amended and restated employment agreements with CEO Gary Atkinson and CFO & General Counsel Alex Andre, effective July 22, 2026. These amendments aim to harmonize change-of-control treatment and incorporate new bonus and tax-compliance provisions for both executives. The new agreements supersede …

Algorhythm Holdings Strikes Section 3(a)(10) Settlement; Up to 5M Shares to Retire $1.93M Debt

Algorhythm Holdings has entered into a Section 3(a)(10) settlement with Continuation Capital to resolve $1,928,014 in liabilities. The company may issue up to 5,000,000 common shares in tranches to Continuation Capital, subject to a 19.99% ownership cap, until 120% of the claim amount is …

iRhythm Technologies Inc (IRTC) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for iRhythm Technologies Inc (IRTC), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 14 analysts currently rate IRTC as a "Strong Buy" with an average price target of $220.00. The company's …

Algorhythm Holdings Inc (RIME) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Algorhythm Holdings Inc (RIME), noting its current valuation score of 9.26, which ranks 10th in its industry. It highlights the company's P/E ratio of -0.20 and indicates that relevant data for P/B, P/S, and P/CF ratios have …

Algorhythm Holdings Inc (RIME) Institutional Confidence

This article provides an "Institutional Confidence" score for Algorhythm Holdings Inc (RIME) from TradingKey. It displays the current score, previous score, and a list of major shareholders with their shareholdings and percentage changes. The data shows insights into institutional activity and holdings for the …

Study Data Show Short-Term Holter Monitoring Misses AF Recurrence Post-Ablation in Pregnancy

New real-world study data from iRhythm Holdings Inc. indicate that short-term Holter monitoring often misses atrial fibrillation (AF) recurrence post-ablation and other arrhythmias in pregnant patients. The findings, presented at HRS 2026, suggest a shift towards continuous 14-day monitoring with devices like iRhythm's Zio …

IRTC|iRhythm Technologies Inc|Price:108.010|Chg%:+0.340

This article provides an in-depth analysis of iRhythm Technologies Inc. (IRTC), highlighting its relatively healthy fundamentals, high growth potential, and "Strong Buy" analyst rating with a target price of $178.00. Despite recent stock market underperformance, the company's valuation is considered fair within its industry, …

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law, a shareholder litigation law firm, is investigating potential breaches of fiduciary duties by officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) due to alleged self-dealing. The firm is encouraging long-term RYTM stockholders to contact them for a free consultation regarding potential …

RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth

Rhythm Pharmaceuticals (RYTM) stock is trading within its recent range as the company reports double-digit revenue growth for its rare obesity therapy, setmelanotide. Q1 2026 revenue reached $29 million, up 38% year-over-year, driven by increased patient uptake. While the company remains loss-making, its operating …

Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4

Rhythm Pharmaceuticals (Nasdaq: RYTM) will report its second-quarter 2026 financial results and provide a corporate update during a live conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET. The company, a commercial-stage biopharmaceutical firm, focuses on rare neuroendocrine diseases, with …

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Rhythm Pharmaceuticals, Inc. announced it will host a conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on rare …

Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside

Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focusing on treatments for rare neuroendocrine diseases, driving investor interest with strong analyst ratings and growth potential. Despite current negative EPS and high R&D costs, its 83.8% revenue growth and flagship product IMCIVREE in Phase 3 …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (IRTC) and its officers/directors. Investors who purchased iRhythm securities before January 11, 2022, and still hold them, are encouraged to participate in the investigation by visiting the …

Frontier tech research, news & data

The article provides interest coverage data for Algorhythm Holdings, Inc. (RIME), noting that its interest coverage was — in FY2025 and on a trailing-twelve-month basis as of Q1 FY26. It further details the company's annual and quarterly interest coverage ratios from FY2009 to Q1 …